T-Therapeutics Raises $133M for TCR Cancer and Autoimmune Drugs

· Health · United Kingdom

U.K. biotech T-Therapeutics has raised a $133 million megaround to advance T cell receptor therapies for cancer and autoimmune disease. Johnson & Johnson, Merck KGaA and Eli Lilly are joining Sanofi in backing the company, which is built around technology it claims can target known but previously undruggable cancer targets and design particularly selective autoimmune treatments. The round lands as investors show renewed appetite for next-generation antibody and receptor-based platforms that could extend beyond existing checkpoint therapies.

Why it matters：Large pharma participation signals that T cell receptor platforms are moving toward the industry's mainstream deal flow, a trend that could broaden treatment options for solid tumors and autoimmune conditions.

Key points

  • T-Therapeutics raised a $133 million round for TCR-based therapies.
  • J&J, Merck KGaA and Eli Lilly joined Sanofi as backers.
  • The company targets hard-to-drug cancer targets and selective autoimmune treatments.

Sources (original reporting)

More stories from this day